Phase 3 trial of cenegermin-bkbj for PCED enrolls first US patient
The first patient in the United States has been dosed in a Phase 3 clinical trial evaluating cenegermin-bkbj ophthalmic solution for the treatment of persistent corneal epithelial defect (PCED), according to a press release from Dompé. The multicenter, randomized, double-masked study, known as Orunea, is comparing cenegermin-bkbj with placebo to assess its ability to achieve... ...
